Not recruiting
Registered drug
Study on the Effects of Atacicept in Adults with IgA Nephropathy
Registered drug
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Atacicept
Find therapies in clinical trials near you – page 54
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
682 trials match your criteria
Not recruiting
Hidradenitis
Not recruitingInvestigational
Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
Not recruiting
Hormone receptor positive HER2 negative breast cancer
Not recruitingRegistered drugNo placebo
Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer
Registered drugNo placebo
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:AbemaciclibCapivasertib+3
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Abemaciclib
Not recruiting
Colitis ulcerative
Not recruitingInvestigational
Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis
Investigational
- Disease:Colitis ulcerative
- Substances:Obefazimod
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Obefazimod
Not recruiting
Hidradenitis
Not recruitingInvestigational
Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:Spesolimab
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Spesolimab
Not recruiting
Colitis ulcerative
Not recruitingInvestigational
Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis
Investigational
- Disease:Colitis ulcerative
- Substances:Obefazimod
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Obefazimod
Not recruiting
Cardiac amyloidosis
Not recruitingRegistered drugNo placebo
Study on Long-Term Safety of Eplontersen for Adults with Transthyretin-Mediated Amyloid Cardiomyopathy
Registered drugNo placebo
- Disease:Cardiac amyloidosis
- Substances:Ascorbic Acid BpEplontersen+8
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Ascorbic Acid Bp
Not recruiting
Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure
Not recruitingRegistered drugNo placebo
Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure
Registered drugNo placebo
- Substances:RisankizumabUstekinumab
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Risankizumab
Not recruiting
Endometrial cancer+4
Not recruitingRegistered drugNo placebo
Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer
Registered drugNo placebo
- Disease:Endometrial cancerTransitional cell carcinoma+3
- Substances:Anhydrous CaffeineParacetamol Dc+3
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Anhydrous Caffeine
Not recruiting
Osteoarthritis
Not recruitingInvestigational
Study on the Effects of RHH646 for Patients with Knee Osteoarthritis
Investigational
- Disease:Osteoarthritis
- Substances:Rhh646
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Rhh646
Not recruiting
Breast cancer+2
Not recruitingRegistered drugNo placebo
Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation
Registered drugNo placebo
- Disease:Breast cancerBreast cancer metastatic+1
- Substances:AlpelisibFulvestrant+3
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Alpelisib
Not recruiting
Cardiovascular disorder
Not recruitingRegistered drug
Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
Registered drug
- Disease:Cardiovascular disorder
- Substances:Acetylsalicylic AcidClopidogrel+1
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Acetylsalicylic Acid